To illustrate the financial effects of the launch of a biosimilar trastuzumab in the treatment of human epidermal growth factor receptor 2-positive breast cancer, Chai et al. [42] built a budget impact model from a payer’s perspective in China. The gene discussed is ERBB2; the disease is breast cancer.